Debt-to-equity of Zentalis Pharmaceuticals, Inc. from 30 Sep 2021 to 30 Sep 2025

Taxonomy & unit
ratio: %
Description
Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary
Zentalis Pharmaceuticals, Inc. quarterly Debt-to-equity in % history and change rate from 30 Sep 2021 to 30 Sep 2025.
  • Zentalis Pharmaceuticals, Inc. Debt-to-equity for the quarter ending 30 Sep 2025 was 29%, a 12% increase year-over-year.
Debt-to-equity, Quarterly (%)
Debt-to-equity, YoY Quarterly Change (%)

Zentalis Pharmaceuticals, Inc. Quarterly Debt-to-equity (%)

Period Value YoY Chg Change % Date
Q3 2025 29% +3.1% +12% 30 Sep 2025
Q2 2025 28% +4% +16% 30 Jun 2025
Q1 2025 28% +6.4% +30% 31 Mar 2025
Q4 2024 26% +2.9% +13% 31 Dec 2024
Q3 2024 26% +3.1% +14% 30 Sep 2024
Q2 2024 24% +1.2% +5.1% 30 Jun 2024
Q1 2024 22% -1.7% -7.1% 31 Mar 2024
Q4 2023 23% -0.71% -3% 31 Dec 2023
Q3 2023 23% -1.2% -5.2% 30 Sep 2023
Q2 2023 23% +2.6% +12% 30 Jun 2023
Q1 2023 24% +3.6% +18% 31 Mar 2023
Q4 2022 24% +7.4% +46% 31 Dec 2022
Q3 2022 24% +12% +95% 30 Sep 2022
Q2 2022 20% 30 Jun 2022
Q1 2022 20% 31 Mar 2022
Q4 2021 16% 31 Dec 2021
Q3 2021 12% 30 Sep 2021
* An asterisk sign (*) next to the value indicates that the value is likely invalid.